bioRxiv Science⌕ Search

Biology subjects

Bhide, M.

Publications and source records attributed to Bhide, M..

3 recordsLinked to original sources

Muon Reduces the Training Cost of Regulatory DNA Transformers

Gene-therapy design depends on identifying regulatory sequences that drive the right level, timing, and cell-type specificity of expression. Regulatory DNA models offer a way to prioritize such sequences computationally before committing candidates to biological testing. Biological validation involves DNA synthesis, cloning, cell culture, sequencing, and functional screening, so training compute is part of the same constrained discovery pipeline rather than an isolated modeling expense. Reducing the compute required to reach a target pretraining quality could shift time and budget toward larger candidate screens, additional assays, more cell contexts, and broader follow-up validation. Given that Adam-style optimizers are widely used for training genomic sequence models, we study whether Muon can provide a more compute-efficient alternative for regulatory DNA pretraining. We provide an in-depth analysis by training Transformer models (26M-420M parameters) on ENCODE cis-regulatory sequences with Adam and Muon while holding architecture, data, and non-optimizer hyperparameters fixed and varying optimizer family, norm-control scheme, learning rate, and model width. In the largest-scale matched-target comparison, Muon reaches Adam-matched perplexity targets with a median FLOP reduction of 35.4% and a median wall-clock time reduction of 38.5%. The analysis further shows that optimizer rankings depend on norm control: independent weight decay pairs more favorably with Muon than Hyperball in this setting. These findings indicate that optimizer update structure and norm-control choices are practical levers for reducing the training resources required to reach matched perplexity targets in regulatory DNA pretraining.

genomics↗

Analog of Kynurenic Acid Decreases Tau Pathology by Modulating Astrogliosis in Rat Model for Tauopathy.

Background and purposeKynurenines have immunomodulatory and neuroactive properties and can influence the central nervous system. Previous studies showed the involvement of the kynurenines in the pathogenesis and progression of neurodegenerative disease. In neurodegenerative disorders, including tauopathies, the tryptophan metabolism is shifted toward neurotoxic agents and the reduction of neuroprotectant products. Astrocyte-derived kynurenic acid serves as a neuroprotectant. However, systemic administration of kynurenic acid is not effective because of low permeability across the blood-brain barrier (BBB). Experimental ApproachWe used a kynurenic acid analog with similar biological activity but higher brain permeability to overcome BBB limitations. In the present study, we used amide derivate of kynurenic acid N-(2-N, N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamid (KYNA-1). We administered KYNA-1 for three months to tau transgenic rats SHR-24 and analyzed the effect on tau pathology and activation of glial cells. Primary glial cell cultures were applied to identify the mechanism of the KYNA-1 effect. Key resultsKYNA-1 was not toxic to rats after chronic three-month administration. When chronically administered, KYNA-1 reduced hyperphosphorylation of insoluble tau in the brain of transgenic rats. Noteworthily, the plasma total tau was also reduced. We determined that the effect of KYNA-1 on tau pathology was induced through the modulation of glial activation. KYNA-1 inhibited LPS induced activation of astrocytes and induced transformation of microglia to M2 phenotype. Conclusion and ImplicationsWe identified that the administration of KYNA-1 reduced tau hyperphosphorylation and neuroinflammation. KYNA-1 may serve as a promising treatment for tauopathies. What is already known?O_LIStudies showed tryptophan-kynurenine pathway changes in neurodegenerative disorders including tauopathies C_LIO_LIKynurenines exert immunomodulatory and neuroactive properties and have influence on the central nervous system C_LI What does this study add?O_LIChronic administration of synthetic analog of kynurenic acid (KYNA-1) reduces tau phosphorylation and astrogliosis in a transgenic rat model for tauopathies C_LIO_LIThe analog reversed LPS-induced inflammatory changes in glial cell cultures C_LI What is the clinical significance?O_LIAdministration of KYNA-1 analog shifted the tryptophan metabolism in the neuroprotectant direction C_LIO_LINeuroprotective analogs KYNA-1 can serve as a new and effective potential therapeutic approach for tauopathies C_LI

neuroscience↗

Ehrlichia ruminantium uses its transmembrane protein Ape to adhere to host bovine aortic endothelial cells

AO_SCPLOWBSTRACTC_SCPLOWEhrlichia ruminantium is an obligate intracellular bacterium, transmitted by ticks of the genus Amblyomma and responsible for heartwater, a disease of domestic and wild ruminants. High genetic diversity of E. ruminantium strains hampers the development of an effective vaccine against all strains present in the field. In order to develop strategies for the control of heartwater through both vaccine and alternative therapeutic approaches, it is important to first gain a better understanding of the early interaction of E. ruminantium and its host cell. Particularly, the mechanisms associated with bacterial adhesion remain to be elucidated. Herein, we studied the role of E. ruminantium membrane protein ERGA_CDS_01230 (UniProt Q5FFA9), a probable iron transporter, in the adhesion process to host bovine aortic endothelial cells (BAEC). The recombinant version of the protein ERGA_CDS_01230, successfully produced in the Leishmania tarentolae system, is O-glycosylated. Following in vitro culture of E. ruminantium in BAEC, the expression of CDS ERGA_CDS_01230 peaks at the extracellular infectious elementary body stages. This result suggest the likely involvement of ERGA_CDS_01230, named hereafter Ape for Adhesion protein of Ehrlichia, in the early interaction of E. ruminantium with its host cells. We showed using flow cytometry and scanning electron microscopy that beads coated with recombinant ERGA_CDS_01230 (rApe) adheres to BAEC. In addition, we also observed that rApe interacts with proteins of the cell lysate, membrane and organelle fractions. Additionally, enzymatic treatment degrading dermatan and chondroitin sulfates on the surface of BAEC is associated with a 50% reduction in the number of bacteria in the host cell after a developmental cycle, indicating that glycosaminoglycans seem to play a role in the adhesion of E. ruminantium to the host cell. Finally, Ape induces a humoral response in vaccinated animals. Globally, our work identifying the role of Ape in E. ruminantium adhesion to host cells makes it a gold vaccine candidate and represents a first step toward the understanding of the mechanisms of cell invasion by E. ruminantium.

microbiology↗